Cover Image
市場調查報告書

腸炎:開發中產品分析

Enterocolitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 293885
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
腸炎:開發中產品分析 Enterocolitis - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 43 Pages
簡介

腸炎指的是大腸及小腸發炎的疾病。主要的症狀有發燒及腹部飽脹、噁心、下痢、直腸出血、倦怠感等。腸炎主要是由於腸內組織發炎、胃內食物滯留、腹壁的紅斑症、無呼吸發作、化膿、心血管虛脫等。主要治療法包含了抗生素等。

本報告提供全球各國的腸炎(全腸炎,小腸結腸炎)所用的開發中產品之開發情形相關分析,提供您開發中產品的開發·上市最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

腸炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腸炎:企業開發中的治療藥

腸炎:大學/機關研究中的治療藥

腸炎:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

腸炎:企業開發中的產品

腸炎:大學/機關研究中的產品

腸炎的治療藥開發企業

  • Angothera GmbH
  • AvidBiotics Corp.
  • Infant Bacterial Therapeutics AB
  • Sigma-Tau Pharmaceuticals, Inc

腸炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腸炎:最近的開發平台趨勢

腸炎:暫停中的計劃

腸炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8602IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Enterocolitis - Pipeline Review, H2 2016, provides an overview of the Enterocolitis (Gastrointestinal) pipeline landscape.

Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include Inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Enterocolitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Enterocolitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Enterocolitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 5 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Enterocolitis.

Enterocolitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Enterocolitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Enterocolitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Enterocolitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Enterocolitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Enterocolitis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Enterocolitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Enterocolitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Enterocolitis Overview
  • Therapeutics Development
    • Pipeline Products for Enterocolitis - Overview
    • Pipeline Products for Enterocolitis - Comparative Analysis
  • Enterocolitis - Therapeutics under Development by Companies
  • Enterocolitis - Therapeutics under Investigation by Universities/Institutes
  • Enterocolitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Enterocolitis - Products under Development by Companies
  • Enterocolitis - Products under Investigation by Universities/Institutes
  • Enterocolitis - Companies Involved in Therapeutics Development
    • Angothera GmbH
    • AvidBiotics Corp.
    • Infant Bacterial Therapeutics AB
    • Sigma-Tau Pharmaceuticals, Inc
  • Enterocolitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibodies for Enterocolitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AvR2-V10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-34 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBP-9414 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melatonin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRG-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Necrotizing Enterocolitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STP-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Enterocolitis - Dormant Projects
  • Enterocolitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial
      • Mar 31, 2016: IBT receives Rare Pediatric Disease Designation from FDA for drug candidate
      • Jan 08, 2016: BioGaia's subsidiary IBT has US IND open and Swedish CTA approved for clinical study
      • Jun 24, 2015: BioGaia Subsidiary IBT Takes Rapid Steps in Development of a Drug for Premature Infants
      • Jun 12, 2015: BioGaia evaluates the possibility of a separate listing of Infant Bacterial Therapeutics
      • Mar 26, 2015: Infant Bacterial Therapeutics receives additional funding from mother company BioGaia
      • Feb 23, 2015: BioGaia subsidiary Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Enterocolitis, H2 2016
  • Number of Products under Development for Enterocolitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Enterocolitis - Pipeline by Angothera GmbH, H2 2016
  • Enterocolitis - Pipeline by AvidBiotics Corp., H2 2016
  • Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2016
  • Enterocolitis - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Enterocolitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Enterocolitis, H2 2016
  • Number of Products under Development for Enterocolitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top